Vir Biotechnology to present hepatitis delta treatment results at liver meeting

SAN FRANCISCO - Vir Biotechnology, Inc. (NASDAQ:VIR), a $776 million market cap biotech company currently trading at $5.59, will present Week 48 endpoint results from its SOLSTICE Phase 2 clinical study at the American Association for the Study of Liver Diseases (AASLD) meeting in Washington, D.C., November 7-11, according to a press release statement. According to InvestingPro analysis, the company maintains a strong balance sheet with more cash than debt, though it’s currently experiencing rapid cash burn.

The study evaluates tobevibart alone or in combination with elebsiran in patients with chronic hepatitis delta. These results follow previously reported data showing rapid and sustained rates of virologic suppression at Week 24 and beyond. With the company’s next earnings report due on October 30, investors can access comprehensive analysis and additional insights through InvestingPro’s detailed research reports.

The company will deliver an oral presentation on the efficacy and safety data from the SOLSTICE trial on November 9. Tarik Asselah, Professor of Hepatology at Hôpital Beaujon and the University of Paris, will present the findings.

Additionally, Vir will showcase a poster on November 8 about ECLIPSE, its registrational program currently enrolling patients to evaluate the safety and efficacy of the combination therapy in chronic hepatitis delta patients. Nancy Reau from Rush University Medical Center will present this poster.

Tobevibart is an investigational monoclonal antibody targeting hepatitis B surface antigen, designed to inhibit virus entry into liver cells and reduce viral particles in the blood. Elebsiran is an investigational small interfering RNA discovered by Alnylam Pharmaceuticals that aims to degrade hepatitis B virus RNA transcripts. Both are administered subcutaneously.

Chronic hepatitis delta is considered one of the most severe forms of viral hepatitis, occurring as a co-infection with hepatitis B virus. While analyst price targets range from $12 to $31, suggesting significant upside potential, InvestingPro data indicates the company faces near-term challenges with analysts anticipating sales decline in the current year.

In other recent news, Vir Biotechnology reported its second-quarter earnings for 2025, which did not meet expectations. The company experienced a deeper-than-expected loss with an earnings per share of -0.8 USD, compared to the forecasted -0.7 USD. Additionally, revenue was reported at 1.21 million USD, significantly below the anticipated 2.66 million USD. Despite these results, several analysts have expressed positive outlooks for the company. BofA Securities upgraded Vir Biotechnology from Neutral to Buy, raising its price target to 14 USD, citing the potential of Vir’s treatment for severe liver disease caused by hepatitis delta virus. H.C. Wainwright also reiterated its Buy rating with a 15 USD price target after discussions with company management. Meanwhile, Evercore ISI initiated coverage with an Outperform rating and a 12 USD price target, noting a "compelling asymmetric setup" for the company’s future. These developments reflect a mixed but potentially promising outlook for Vir Biotechnology.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.